View source for 20240024434. MITAPIVAT THERAPY AND MODULATORS OF CYTOCHROME P450 simplified abstract (Agios Pharmaceuticals, Inc.)

=MITAPIVAT THERAPY AND MODULATORS OF CYTOCHROME P450=


==Organization Name==

[[:Category:Agios Pharmaceuticals, Inc.|Agios Pharmaceuticals, Inc.]]


[[Category:Agios Pharmaceuticals, Inc.]]

==Inventor(s)==

[[:Category:Varsha Venkatachalam Iyer of Boston MA (US)|Varsha Venkatachalam Iyer of Boston MA (US)]][[Category:Varsha Venkatachalam Iyer of Boston MA (US)]]

[[:Category:Chandra Agarwal Prakash of North Andover MA (US)|Chandra Agarwal Prakash of North Andover MA (US)]][[Category:Chandra Agarwal Prakash of North Andover MA (US)]]

[[:Category:Hua Yang of Acton MA (US)|Hua Yang of Acton MA (US)]][[Category:Hua Yang of Acton MA (US)]]

==MITAPIVAT THERAPY AND MODULATORS OF CYTOCHROME P450 - A simplified explanation of the abstract==


This abstract first appeared for US patent application 20240024434 titled 'MITAPIVAT THERAPY AND MODULATORS OF CYTOCHROME P450

==Simplified Explanation==

The patent application describes methods of treating pyruvate kinase deficiency (PKD), sickle cell disease, or thalassemia using a drug called mitapivat or its pharmaceutically acceptable salt. The drug can be used alone or in combination with a secondary drug, such as an inducer or inhibitor of cytochrome p450. The application provides information on various doses and dosing regimens of mitapivat in monotherapy and in combination with other medications.

* Mitapivat or its salt can be used to treat pyruvate kinase deficiency (PKD), sickle cell disease, or thalassemia.
* The drug can be used alone or in combination with a secondary drug, such as an inducer or inhibitor of cytochrome p450.
* The patent application provides information on different doses and dosing regimens of mitapivat in monotherapy and in combination with other medications.

Potential applications of this technology:
* Treatment of pyruvate kinase deficiency (PKD), sickle cell disease, or thalassemia.
* Combination therapy with other drugs to enhance the treatment efficacy.

Problems solved by this technology:
* Lack of effective treatment options for pyruvate kinase deficiency (PKD), sickle cell disease, or thalassemia.
* Limited options for combination therapy in these conditions.

Benefits of this technology:
* Improved treatment outcomes for patients with pyruvate kinase deficiency (PKD), sickle cell disease, or thalassemia.
* Potential for personalized medicine through different doses and dosing regimens.


==Original Abstract Submitted==

described herein are methods of treating pyruvate kinase deficiency (pkd), sickle cell disease or thalassemia with mitapivat or a pharmaceutically acceptable salt thereof, or use of the drug for the treatment of these conditions, in combination with or in the absence of with a secondary drug, such as an inducer or an inhibitor of cytochrome p450. various doses and dosing regimens of mitapivat in monotherapy and in concomitant medications are described.



[[Category:A61K38/45]]